Safety and immunogenicity of 13-valent pneumococcal conjugate vaccine formulations with and without aluminum phosphate and comparison of the formulation of choice with 23-valent pneumococcal polysaccharide vaccine in elderly adults A randomized open-label trial

被引:28
|
作者
Juergens, Christine [1 ]
de Villiers, Pierre J. T. [2 ]
Moodley, Keymanthri [2 ]
Jayawardene, Deepthi [3 ]
Jansen, Kathrin U. [3 ]
Scott, Daniel A. [3 ]
Emini, Emilio A. [3 ]
Gruber, William C. [3 ]
Schmoele-Thoma, Beate [1 ]
机构
[1] Pfizer GmbH, Berlin, Germany
[2] Univ Stellenbosch, ZA-7505 Tygerberg, South Africa
[3] Pfizer Inc, Pearl River, NY USA
关键词
13-valent pneumococcal conjugate vaccine; 23-valent pneumococcal polysaccharide vaccine; adults; elderly; immunogenicity; PCV13; PPSV23; safety; OPSONOPHAGOCYTIC ASSAY; RESPONSES;
D O I
10.4161/hv.27998
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
This randomized open-label trial was designed to provide preliminary immunogenicity and safety data to support development of the pediatric 13-valent pneumococcal conjugate vaccine (PCV13) for adults. The aims were to: identify an age-appropriate PCV13 formulation, i.e., with (n = 309) or without (n = 304) aluminum phosphate (AlPO4); compare the selected PCV13 formulation (n = 309) with 23-valent pneumococcal polysaccharide vaccine (PPSV23; n = 301); and, together with an extension study, assess sequential use of pneumococcal vaccines at 1-year intervals in adults aged >= 65 years (n = 105) not pre-vaccinated with PPSV23. Immune responses were measured by ELISA and opsonophagocytic activity assays 1 month postvaccination. Immunoglobulin G responses elicited by PCV13 with AlPO4 and PCV13 without AlPO4 were similar for the majority, and noninferior for all PCV13 serotypes. PCV13 with AlPO4 was generally more reactogenic, with reactions mainly mild or moderate. Thus, PCV13 with AlPO4 (hereafter PCV13) became the selected formulation. Immune responses to PCV13 were noninferior for all but one serotype and for most PCV13 serotypes superior to PPSV23. Vaccine sequence assessments showed that for PCV13/PPSV23, the initial PCV13 dose generally enhanced responses to a subsequent PPSV23 dose, compared with PPSV23 alone. For PCV13/PCV13, a second dose did not enhance the first dose response when given after 1 year. For PCV13/PPSV23/PCV13, priming with PCV13 (vaccination 1) did not protect against lower responses induced by PPSV23 to subsequent PCV13 (vaccination 3). In conclusion, the pediatric PCV13 formulation with AlPO4 is well tolerated and immunogenic in adults, is generally more immunogenic than PPSV23, and subsequent vaccination with PPSV23 is possible if required.
引用
收藏
页码:1343 / 1353
页数:11
相关论文
共 50 条
  • [1] Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to the 23-valent pneumococcal polysaccharide vaccine in elderly Japanese adults
    Shiramoto, Masanari
    Hanada, Ryuzo
    Juergens, Christine
    Shoji, Yasuko
    Yoshida, Mizuki
    Ballan, Barry
    Cooper, David
    Gruber, William C.
    Scott, Daniel A.
    Schmoele-Thoma, Beate
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2015, 11 (09) : 2198 - 2206
  • [2] Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults
    Jackson, Lisa A.
    Gurtman, Alejandra
    van Cleeff, Martin
    Jansen, Kathrin U.
    Jayawardene, Deepthi
    Devlin, Carmel
    Scott, Daniel A.
    Emini, Emilio A.
    Gruber, William C.
    Schmoele-Thoma, Beate
    VACCINE, 2013, 31 (35) : 3577 - 3584
  • [3] An Open-label Trial to Assess the Safety of 13-Valent Pneumococcal Conjugate Vaccine in Older Adults, Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine.
    Schwarz, T. F.
    Pauksens, K.
    Juergens, C.
    Jayawardene, D.
    Emini, E. A.
    Gruber, W. C.
    Scott, D. A.
    Schmoele-Thoma, B.
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2011, 59 : S30 - S30
  • [4] PHARMACOECONOMIC EVALUATION OF 13-VALENT PNEUMOCOCCAL CONJUGATE AND 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE IN CANADIAN ADULTS
    Chuck, A.
    Waye, A.
    Zanotti, G.
    Jacobs, P.
    Kellner, J.
    Tyrrell, G.
    VALUE IN HEALTH, 2012, 15 (04) : A243 - A243
  • [5] Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults ≥65 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine
    Peterson, James T.
    Stacey, Helen L.
    MacNair, John E.
    Li, Jianing
    Hartzel, Jonathan S.
    Sterling, Tina M.
    Benner, Patrice
    Tamms, Gretchen M.
    Musey, Luwy K.
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2019, 15 (03) : 540 - 548
  • [6] Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine
    Jackson, Lisa A.
    Gurtman, Alejandra
    Rice, Kathryn
    Pauksens, Karlis
    Greenberg, Richard N.
    Jones, Thomas R.
    Scott, Daniel A.
    Emini, Emilio A.
    Gruber, William C.
    Schmoele-Thoma, Beate
    VACCINE, 2013, 31 (35) : 3585 - 3593
  • [7] Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 18-49 years of age, naive to 23-valent pneumococcal polysaccharide vaccine
    Bryant, K. A.
    Frenck, R.
    Gurtman, A.
    Rubino, J.
    Treanor, J.
    Thompson, A.
    Jones, T. R.
    Sundaraiyer, V.
    Baxter, L. M.
    Gruber, W. C.
    Emini, E. A.
    Scott, D. A.
    Schmoele-Thoma, B.
    VACCINE, 2015, 33 (43) : 5854 - 5860
  • [8] Immunogenicity of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Followed by the 23-Valent Pneumococcal Polysaccharide Vaccine (PPSV23) in Adults with and without Immunosuppressive Therapy
    Garcia Garrido, Hannah M.
    Vollaard, Albert
    D'Haens, Geert R.
    Spuls, Phyllis I.
    Bemelman, Frederike J.
    Tanck, Michael W.
    de Bree, Godelieve J.
    Meek, Bob
    Grobusch, Martin P.
    Goorhuis, Abraham
    VACCINES, 2022, 10 (05)
  • [9] Effectiveness of a 23-valent pneumococcal polysaccharide vaccine and a 13-valent pneumococcal conjugate vaccine among the elderly with chronic respiratory diseases
    Masuda, Toshihiro
    Akamatsu, Taisuke
    Nakatani, Eiji
    Tamura, Kanami
    Takahashi, Shingo
    Tanaka, Yuko
    Watanabe, Hirofumi
    Endo, Yoshinari
    Suzuki, Takahito
    Noguchi, Rie
    Saigusa, Mika
    Yamamoto, Akito
    Shishido, Yuichiro
    Akita, Takefumi
    Morita, Satoru
    Asada, Kazuhiro
    Shirai, Toshihiro
    EUROPEAN RESPIRATORY JOURNAL, 2018, 52
  • [10] Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to 23-valent pneumococcal polysaccharide in immunocompetent adults: A systematic review and meta-analysis
    Vadlamudi, Nirma Khatri
    Parhar, Kamalpreet
    Malana, Kim Lorenzo Altre
    Kang, Amy
    Marra, Fawziah
    VACCINE, 2019, 37 (08) : 1021 - 1029